SOW
TRDA icon

State of Wyoming’s Entrada Therapeutics TRDA Stock Holding History

State of Wyoming’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,575
Closed -$50.9K – 2059
2025
Q2 		$50.9K Buy
7,575
+4,295
+131% +$34.6K 0.01% 1564
2025
Q1 		$29.7K Sell
3,280
-2,757
-46% -$34.4K ﹤0.01% 1551
2024
Q4 		$104K Buy
+6,037
New +$109K 0.01% 1164
2024
Q1 		– Sell
-5,932
Closed -$89.5K – 1825
2023
Q4 		$89.5K Buy
+5,932
New +$87.9K 0.02% 1064
2022
Q2 		– Sell
-1,060
Closed -$10K – 2139
2022
Q1 		$10K Buy
1,060
+829
+359% +$8.89K 0.01% 1608
2021
Q4 		$4K Buy
+231
New +$5.6K ﹤0.01% 1742

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

State of Wyoming's TRDA Position: Q3 2025 in Review

State of Wyoming sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 7,575 shares — an estimated $50.9K sold.

State of Wyoming first reported a position in TRDA in Q4 2021 and held it in 6 quarters. The position peaked at $104K in Q4 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • State of Wyoming reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • State of Wyoming sold 7,575 Entrada Therapeutics shares in Q3 2025, an estimated $50.9K.
  • State of Wyoming first reported a position in Entrada Therapeutics in Q4 2021 and held it in 6 quarters.
  • State of Wyoming's Entrada Therapeutics position peaked at $104K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on State of Wyoming's 13F filing for Q3 2025, filed 4 Nov 2025.